Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 4
2015 3
2016 3
2017 3
2018 3
2019 8
2020 7
2021 12
2022 12
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, Robison N, Schorry EK, Shannon K, Stevenson DA, Stieglitz E, Ullrich NJ, Walsh KS, Weiss BD, Wolters PL, Yohay K, Yohe ME, Widemann BC, Fisher MJ. de Blank PMK, et al. Among authors: stieglitz e. Neuro Oncol. 2022 Nov 2;24(11):1845-1856. doi: 10.1093/neuonc/noac165. Neuro Oncol. 2022. PMID: 35788692 Free PMC article. Review.
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. Mandal K, et al. Among authors: stieglitz e. Nat Cancer. 2023 Nov;4(11):1592-1609. doi: 10.1038/s43018-023-00652-6. Epub 2023 Oct 30. Nat Cancer. 2023. PMID: 37904046 Free PMC article.
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.
Wintering A, Hecht A, Meyer J, Wong EB, Hübner J, Abelson S, Feldman K, Kennedy VE, Peretz CAC, French DL, Maguire JA, Jobaliya C, Vasquez MR, Desai S, Dulman R, Nemecek E, Haines H, Hammad M, El Haddad A, Kogan SC, Abdullaev Z, Chehab FF, Tasian SK, Smith CC, Loh ML, Stieglitz E. Wintering A, et al. Among authors: stieglitz e. Haematologica. 2023 Dec 28. doi: 10.3324/haematol.2023.283776. Online ahead of print. Haematologica. 2023. PMID: 38152053 Free article.
Targeting the Ras pathway in pediatric hematologic malignancies.
Pikman Y, Stieglitz E. Pikman Y, et al. Among authors: stieglitz e. Curr Opin Pediatr. 2021 Feb 1;33(1):49-58. doi: 10.1097/MOP.0000000000000981. Epub 2020 Dec 29. Curr Opin Pediatr. 2021. PMID: 33394740 Free PMC article. Review.
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP. Temple WC, et al. Among authors: stieglitz e. J Immunother Cancer. 2023 Nov 24;11(11):e006985. doi: 10.1136/jitc-2023-006985. J Immunother Cancer. 2023. PMID: 38007238 Free PMC article.
Too many white cells-TAM, JMML, or something else?
Satty A, Stieglitz E, Kucine N. Satty A, et al. Among authors: stieglitz e. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):37-42. doi: 10.1182/hematology.2023000464. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066851
Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.
Wintering A, Smith S, Fuh B, Rangaswami A, Dahl G, Chien M, Gruber TA, Dang J, Li LS, Lenzen A, Savelli S, Dvorak CC, Agrawal AK, Stieglitz E. Wintering A, et al. Among authors: stieglitz e. Pediatr Blood Cancer. 2022 May;69(5):e29499. doi: 10.1002/pbc.29499. Epub 2021 Dec 22. Pediatr Blood Cancer. 2022. PMID: 34939322 Free PMC article. Review.
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC. Popescu B, et al. Among authors: stieglitz e. Cell Rep Med. 2023 Nov 21;4(11):101290. doi: 10.1016/j.xcrm.2023.101290. Cell Rep Med. 2023. PMID: 37992684 Free PMC article.
59 results